Shandong Xinhua Pharmaceutical Company Limited (00719) has published its unaudited consolidated results for the nine months ended 30 September 2025. According to the announcement, operating income reached RMB6.76 billion, a 0.42% increase compared to the same period in 2024.

Net profit attributable to shareholders stood at RMB256.22 million, representing a 25.53% decline year-on-year. After deducting non-recurring items, net profit declined by 25.62%. Basic earnings per share were RMB0.37, compared with RMB0.50 in the same period last year, and the ratio of weighted average return on net assets decreased from 7.21% to 5.01%.

The announcement also highlighted positive growth in net cash flow from operating activities, which reached RMB322.00 million, rising 26.65% year-on-year. Total assets were RMB9.09 billion as of 30 September 2025, up 0.82% from the end of 2024, while net assets attributable to shareholders rose by 3.15% to RMB5.15 billion.

The Board noted that the figures for this period were reviewed by the Audit Committee and cautioned shareholders and potential investors to exercise due care when dealing in the company’s securities.